Emergent BioSolutions Inc 2020 SR
The report marks Emergent's inaugural ESG disclosure, highlighting its mission to protect and enhance life through medical countermeasures. Key focus areas include the company's response to the COVID-19 pandemic, where it scaled manufacturing for vaccine candidates, and its efforts to combat the opioid crisis with NARCAN Nasal Spray. The report details the establishment of a formal ESG review process and identifies priority issues such as product quality, safety, and diversity. It also outlines a three-year Quality Enhancement Plan following a manufacturing incident. Environmental stewardship and community engagement through the eGIVE program are also featured.
Company: Emergent BioSolutions Inc
Sector: Manufacturing
Country: United States
Year: 2020
Type: SR
Pages: 32
Emergent BioSolutions Inc
The report marks Emergent's inaugural ESG disclosure, highlighting its mission to protect and enhance life through medical countermeasures. Key focus areas include the company's response to the COVID-19 pandemic, where it scaled manufacturing for vaccine candidates, and its efforts to combat the opioid crisis with NARCAN Nasal Spray. The report details the establishment of a formal ESG review process and identifies priority issues such as product quality, safety, and diversity. It also outlines a three-year Quality Enhancement Plan following a manufacturing incident. Environmental stewardship and community engagement through the eGIVE program are also featured.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Published
Nov 18, 2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees